Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 153 entries
Sorted by: Best Match Show Resources per page
Prepublication.

Science (New York, N.Y.)

Proctor CM.
PMID: 17736291
Science. 1958 May 09;127(3306):1121-2. doi: 10.1126/science.127.3306.1121.

No abstract available.

Cite
Proctor CM. Prepublication. Science. 1958;127(3306):1121-2doi: 10.1126/science.127.3306.1121.
Proctor, C. M. (1958). Prepublication. Science (New York, N.Y.), 127(3306), 1121-2. https://doi.org/10.1126/science.127.3306.1121
Proctor, C M. "Prepublication." Science (New York, N.Y.) vol. 127,3306 (1958): 1121-2. doi: https://doi.org/10.1126/science.127.3306.1121
Proctor CM. Prepublication. Science. 1958 May 09;127(3306):1121-2. doi: 10.1126/science.127.3306.1121. PMID: 17736291.
Copy Download .nbib Format: NLM
CuWO.

Chemical communications (Cambridge, England)

Proctor AD, Panuganti S, Bartlett BM.
PMID: 29333550
Chem Commun (Camb). 2018 Jan 25;54(9):1101-1104. doi: 10.1039/c7cc07611h.

The aerobic photochemical oxidation of benzylamine was carried out on the ternary oxides CuWO

Cite
Proctor AD, Panuganti S, Bartlett BM. CuWO. Chem Commun (Camb). 2018;54(9):1101-1104doi: 10.1039/c7cc07611h.
Proctor, A. D., Panuganti, S., & Bartlett, B. M. (2018). CuWO. Chemical communications (Cambridge, England), 54(9), 1101-1104. https://doi.org/10.1039/c7cc07611h
Proctor, Aaron D, et al. "CuWO." Chemical communications (Cambridge, England) vol. 54,9 (2018): 1101-1104. doi: https://doi.org/10.1039/c7cc07611h
Proctor AD, Panuganti S, Bartlett BM. CuWO. Chem Commun (Camb). 2018 Jan 25;54(9):1101-1104. doi: 10.1039/c7cc07611h. PMID: 29333550.
Copy Download .nbib Format: NLM
Passage of Latchkey through the Intestinal Canal.

Edinburgh medical journal

Lediard HA, Rinaldi C, Proctor CP.
PMID: 29640997
Edinb Med J. 1922 Oct;29(4):213-214.

No abstract available.

Cite
Lediard HA, Rinaldi C, Proctor CP. Passage of Latchkey through the Intestinal Canal. Edinb Med J. 1922;29(4):213-214
Lediard, H. A., Rinaldi, C., & Proctor, C. P. (1922). Passage of Latchkey through the Intestinal Canal. Edinburgh medical journal, 29(4), 213-214.
Lediard, H A, et al. "Passage of Latchkey through the Intestinal Canal." Edinburgh medical journal vol. 29,4 (1922): 213-214.
Lediard HA, Rinaldi C, Proctor CP. Passage of Latchkey through the Intestinal Canal. Edinb Med J. 1922 Oct;29(4):213-214. PMID: 29640997; PMCID: PMC5316569.
Copy Download .nbib Format: NLM
Tree Nut Consumption and Adipose Tissue Mass: Mechanisms of Action.

Current developments in nutrition

Tindall AM, Petersen KS, Lamendella R, Shearer GC, Murray-Kolb LE, Proctor DN, Kris-Etherton PM.
PMID: 30488045
Curr Dev Nutr. 2018 Aug 03;2(11):nzy069. doi: 10.1093/cdn/nzy069. eCollection 2018 Nov.

There is concern that tree nuts may cause weight gain due to their energy density, yet evidence shows that tree nuts do not adversely affect weight status. Epidemiologic and experimental studies have shown a reduced risk of chronic diseases...

Cite
Tindall AM, Petersen KS, Lamendella R, et al. Tree Nut Consumption and Adipose Tissue Mass: Mechanisms of Action. Curr Dev Nutr. 2018;2(11):nzy069doi: 10.1093/cdn/nzy069.
Tindall, A. M., Petersen, K. S., Lamendella, R., Shearer, G. C., Murray-Kolb, L. E., Proctor, D. N., & Kris-Etherton, P. M. (2018). Tree Nut Consumption and Adipose Tissue Mass: Mechanisms of Action. Current developments in nutrition, 2(11), nzy069. https://doi.org/10.1093/cdn/nzy069
Tindall, Alyssa M, et al. "Tree Nut Consumption and Adipose Tissue Mass: Mechanisms of Action." Current developments in nutrition vol. 2,11 (2018): nzy069. doi: https://doi.org/10.1093/cdn/nzy069
Tindall AM, Petersen KS, Lamendella R, Shearer GC, Murray-Kolb LE, Proctor DN, Kris-Etherton PM. Tree Nut Consumption and Adipose Tissue Mass: Mechanisms of Action. Curr Dev Nutr. 2018 Aug 03;2(11):nzy069. doi: 10.1093/cdn/nzy069. eCollection 2018 Nov. PMID: 30488045; PMCID: PMC6252345.
Copy Download .nbib Format: NLM
Small-Scale Heterogeneity in Drinking Water Biofilms.

Frontiers in microbiology

Neu L, Proctor CR, Walser JC, Hammes F.
PMID: 31736893
Front Microbiol. 2019 Oct 29;10:2446. doi: 10.3389/fmicb.2019.02446. eCollection 2019.

Biofilm heterogeneity has been characterized on various scales for both natural and engineered ecosystems. This heterogeneity has been attributed to spatial differences in environmental factors. Understanding their impact on localized biofilm heterogeneity in building plumbing systems is important for...

Cite
Neu L, Proctor CR, Walser JC, et al. Small-Scale Heterogeneity in Drinking Water Biofilms. Front Microbiol. 2019;10:2446doi: 10.3389/fmicb.2019.02446.
Neu, L., Proctor, C. R., Walser, J. C., & Hammes, F. (2019). Small-Scale Heterogeneity in Drinking Water Biofilms. Frontiers in microbiology, 102446. https://doi.org/10.3389/fmicb.2019.02446
Neu, Lisa, et al. "Small-Scale Heterogeneity in Drinking Water Biofilms." Frontiers in microbiology vol. 10 (2019): 2446. doi: https://doi.org/10.3389/fmicb.2019.02446
Neu L, Proctor CR, Walser JC, Hammes F. Small-Scale Heterogeneity in Drinking Water Biofilms. Front Microbiol. 2019 Oct 29;10:2446. doi: 10.3389/fmicb.2019.02446. eCollection 2019. PMID: 31736893; PMCID: PMC6828615.
Copy Download .nbib Format: NLM
Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation.

Science advances

West J, Satapathy S, Whiten DR, Kelly M, Geraghty NJ, Proctor EJ, Sormanni P, Vendruscolo M, Buxbaum JN, Ranson M, Wilson MR.
PMID: 34890220
Sci Adv. 2021 Dec 10;7(50):eabf7606. doi: 10.1126/sciadv.abf7606. Epub 2021 Dec 10.

[Figure: see text].

Cite
West J, Satapathy S, Whiten DR, et al. Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation. Sci Adv. 2021;7(50):eabf7606doi: 10.1126/sciadv.abf7606.
West, J., Satapathy, S., Whiten, D. R., Kelly, M., Geraghty, N. J., Proctor, E. J., Sormanni, P., Vendruscolo, M., Buxbaum, J. N., Ranson, M., & Wilson, M. R. (2021). Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation. Science advances, 7(50), eabf7606. https://doi.org/10.1126/sciadv.abf7606
West, Jennifer, et al. "Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation." Science advances vol. 7,50 (2021): eabf7606. doi: https://doi.org/10.1126/sciadv.abf7606
West J, Satapathy S, Whiten DR, Kelly M, Geraghty NJ, Proctor EJ, Sormanni P, Vendruscolo M, Buxbaum JN, Ranson M, Wilson MR. Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation. Sci Adv. 2021 Dec 10;7(50):eabf7606. doi: 10.1126/sciadv.abf7606. Epub 2021 Dec 10. PMID: 34890220.
Copy Download .nbib Format: NLM
Implementing evidence-based practices in nonspecialty mental health settings.

Families, systems & health : the journal of collaborative family healthcare

Wolk CB, Arnold KT, Proctor EK.
PMID: 35007120
Fam Syst Health. 2022 Jan 10; doi: 10.1037/fsh0000506. Epub 2022 Jan 10.

OBJECTIVE: Mental health services are often implemented in settings in which mental health is not the primary mission. Schools, primary care clinics, criminal justice and child welfare institutions, and senior centers have been increasingly adding mental health care to...

Cite
Wolk CB, Arnold KT, Proctor EK. Implementing evidence-based practices in nonspecialty mental health settings. Fam Syst Health. 2022;doi: 10.1037/fsh0000506.
Wolk, C. B., Arnold, K. T., & Proctor, E. K. (2022). Implementing evidence-based practices in nonspecialty mental health settings. Families, systems & health : the journal of collaborative family healthcare, . https://doi.org/10.1037/fsh0000506
Wolk, Courtney Benjamin, et al. "Implementing evidence-based practices in nonspecialty mental health settings." Families, systems & health : the journal of collaborative family healthcare vol. (2022). doi: https://doi.org/10.1037/fsh0000506
Wolk CB, Arnold KT, Proctor EK. Implementing evidence-based practices in nonspecialty mental health settings. Fam Syst Health. 2022 Jan 10; doi: 10.1037/fsh0000506. Epub 2022 Jan 10. PMID: 35007120.
Copy Download .nbib Format: NLM
The development of Couple HOPES: a guided online intervention for PTSD and relationship satisfaction enhancement.

European journal of psychotraumatology

Monson CM, Fitzpatrick S, Wagner AC, Valela R, Whitfield KM, Varma S, Landy MSH, Di Bartolomeo A, Crenshaw AO, Fulham L, Morland L, Knopp K, Proctor DW, Toller A, Webster K, Doss BD.
PMID: 34104350
Eur J Psychotraumatol. 2021 May 25;12(1):1917879. doi: 10.1080/20008198.2021.1917879.

No abstract available.

Cite
Monson CM, Fitzpatrick S, Wagner AC, et al. The development of Couple HOPES: a guided online intervention for PTSD and relationship satisfaction enhancement. Eur J Psychotraumatol. 2021;12(1):1917879doi: 10.1080/20008198.2021.1917879.
Monson, C. M., Fitzpatrick, S., Wagner, A. C., Valela, R., Whitfield, K. M., Varma, S., Landy, M. S. H., Di Bartolomeo, A., Crenshaw, A. O., Fulham, L., Morland, L., Knopp, K., Proctor, D. W., Toller, A., Webster, K., & Doss, B. D. (2021). The development of Couple HOPES: a guided online intervention for PTSD and relationship satisfaction enhancement. European journal of psychotraumatology, 12(1), 1917879. https://doi.org/10.1080/20008198.2021.1917879
Monson, Candice M, et al. "The development of Couple HOPES: a guided online intervention for PTSD and relationship satisfaction enhancement." European journal of psychotraumatology vol. 12,1 (2021): 1917879. doi: https://doi.org/10.1080/20008198.2021.1917879
Monson CM, Fitzpatrick S, Wagner AC, Valela R, Whitfield KM, Varma S, Landy MSH, Di Bartolomeo A, Crenshaw AO, Fulham L, Morland L, Knopp K, Proctor DW, Toller A, Webster K, Doss BD. The development of Couple HOPES: a guided online intervention for PTSD and relationship satisfaction enhancement. Eur J Psychotraumatol. 2021 May 25;12(1):1917879. doi: 10.1080/20008198.2021.1917879. PMID: 34104350; PMCID: PMC8158260.
Copy Download .nbib Format: NLM
Cutaneous Vasculitis After Ustekinumab Induction in Crohn's Disease.

Inflammatory bowel diseases

Chugh R, Proctor DD, Little A, Myung P, Cowper S, Imaeda S, Pashankar DS, Al-Bawardy B.
PMID: 33179735
Inflamm Bowel Dis. 2021 Feb 16;27(3):e30-e31. doi: 10.1093/ibd/izaa285.

No abstract available.

Cite
Chugh R, Proctor DD, Little A, et al. Cutaneous Vasculitis After Ustekinumab Induction in Crohn's Disease. Inflamm Bowel Dis. 2021;27(3):e30-e31doi: 10.1093/ibd/izaa285.
Chugh, R., Proctor, D. D., Little, A., Myung, P., Cowper, S., Imaeda, S., Pashankar, D. S., & Al-Bawardy, B. (2021). Cutaneous Vasculitis After Ustekinumab Induction in Crohn's Disease. Inflammatory bowel diseases, 27(3), e30-e31. https://doi.org/10.1093/ibd/izaa285
Chugh, Rishika, et al. "Cutaneous Vasculitis After Ustekinumab Induction in Crohn's Disease." Inflammatory bowel diseases vol. 27,3 (2021): e30-e31. doi: https://doi.org/10.1093/ibd/izaa285
Chugh R, Proctor DD, Little A, Myung P, Cowper S, Imaeda S, Pashankar DS, Al-Bawardy B. Cutaneous Vasculitis After Ustekinumab Induction in Crohn's Disease. Inflamm Bowel Dis. 2021 Feb 16;27(3):e30-e31. doi: 10.1093/ibd/izaa285. PMID: 33179735.
Copy Download .nbib Format: NLM
Novel and Emerging Therapies for Inflammatory Bowel Disease.

Frontiers in pharmacology

Al-Bawardy B, Shivashankar R, Proctor DD.
PMID: 33935763
Front Pharmacol. 2021 Apr 14;12:651415. doi: 10.3389/fphar.2021.651415. eCollection 2021.

Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease are chronic, relapsing and remitting disorders of intestinal inflammation with potential systemic manifestations. Despite the availability of current biologics, such as anti-tumor necrosis factor (anti-TNF), anti-integrins, anti-interleukins and...

Cite
Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol. 2021;12:651415doi: 10.3389/fphar.2021.651415.
Al-Bawardy, B., Shivashankar, R., & Proctor, D. D. (2021). Novel and Emerging Therapies for Inflammatory Bowel Disease. Frontiers in pharmacology, 12651415. https://doi.org/10.3389/fphar.2021.651415
Al-Bawardy, Badr, et al. "Novel and Emerging Therapies for Inflammatory Bowel Disease." Frontiers in pharmacology vol. 12 (2021): 651415. doi: https://doi.org/10.3389/fphar.2021.651415
Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol. 2021 Apr 14;12:651415. doi: 10.3389/fphar.2021.651415. eCollection 2021. PMID: 33935763; PMCID: PMC8080036.
Copy Download .nbib Format: NLM
Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation.

Science advances

West J, Satapathy S, Whiten DR, Kelly M, Geraghty NJ, Proctor EJ, Sormanni P, Vendruscolo M, Buxbaum JN, Ranson M, Wilson MR.
PMID: 34890220
Sci Adv. 2021 Dec 10;7(50):eabf7606. doi: 10.1126/sciadv.abf7606. Epub 2021 Dec 10.

[Figure: see text].

Cite
West J, Satapathy S, Whiten DR, et al. Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation. Sci Adv. 2021;7(50):eabf7606doi: 10.1126/sciadv.abf7606.
West, J., Satapathy, S., Whiten, D. R., Kelly, M., Geraghty, N. J., Proctor, E. J., Sormanni, P., Vendruscolo, M., Buxbaum, J. N., Ranson, M., & Wilson, M. R. (2021). Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation. Science advances, 7(50), eabf7606. https://doi.org/10.1126/sciadv.abf7606
West, Jennifer, et al. "Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation." Science advances vol. 7,50 (2021): eabf7606. doi: https://doi.org/10.1126/sciadv.abf7606
West J, Satapathy S, Whiten DR, Kelly M, Geraghty NJ, Proctor EJ, Sormanni P, Vendruscolo M, Buxbaum JN, Ranson M, Wilson MR. Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation. Sci Adv. 2021 Dec 10;7(50):eabf7606. doi: 10.1126/sciadv.abf7606. Epub 2021 Dec 10. PMID: 34890220; PMCID: PMC8664251.
Copy Download .nbib Format: NLM
Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics.

Breast cancer research and treatment

Lewis Phillips G, Guo J, Kiefer JR, Proctor W, Bumbaca Yadav D, Dybdal N, Shen BQ.
PMID: 34708303
Breast Cancer Res Treat. 2021 Oct 27; doi: 10.1007/s10549-021-06427-w. Epub 2021 Oct 27.

PURPOSE: Assessment of non-clinical safety signals relies on understanding species selectivity of antibodies. This is particularly important with antibody-drug conjugates, where it is key to determine target-dependent versus target-independent toxicity. Although it appears to be widely accepted that trastuzumab...

Cite
Lewis Phillips G, Guo J, Kiefer JR, et al. Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. Breast Cancer Res Treat. 2021;doi: 10.1007/s10549-021-06427-w.
Lewis Phillips, G., Guo, J., Kiefer, J. R., Proctor, W., Bumbaca Yadav, D., Dybdal, N., & Shen, B. Q. (2021). Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. Breast cancer research and treatment, . https://doi.org/10.1007/s10549-021-06427-w
Lewis Phillips, Gail, et al. "Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics." Breast cancer research and treatment vol. (2021). doi: https://doi.org/10.1007/s10549-021-06427-w
Lewis Phillips G, Guo J, Kiefer JR, Proctor W, Bumbaca Yadav D, Dybdal N, Shen BQ. Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. Breast Cancer Res Treat. 2021 Oct 27; doi: 10.1007/s10549-021-06427-w. Epub 2021 Oct 27. PMID: 34708303.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 153 entries